Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07383077Completed

Molecular Determinants of Spinal Cord Injury Rehabilitation

Role: collaborator

NCT06915610Not ApplicableEnrolling By Invitation

Reengineering Cervical Cancer Screening for the 21st Century: Joint Action for a Novel Up-to-date and Sustainable Screening Program

Role: collaborator

NCT06892106Completed

Gut Dysbiosis in Spinal Cord Injury Rehabilitation

Role: collaborator

NCT06498167Recruiting

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

Role: collaborator

All 4 trials loaded